On a recent trip to Washington D.C., the Chief Executive of the MHRA Lawrence Tallon outlined the agency’s strategic direction.
Mr Tallon stated his intention to build a world-class safety and surveillance system enabled by comprehensive real-world data for the protection of patients and the public.
In line with BIVDA’s priorities, he also signalled that the agency seeks to accelerate access to new medicines, medical products and technologies with rapid, efficient decisions on clinical trials and core licensing.
In keeping with the government’s broader objectives, Mr Tallon revealed that the MHRA would focus on innovation to drive up the MHRA’s contribution to UK life sciences for the benefit of the public, the NHS and economic growth.
